Gene Therapy (Onasemnogene Abeparvovec) Is Safe and Effective in Children with Spinal Muscular Atrophy Type 1 on Invasive Long-Term Ventilation

被引：0
|
作者：
Narayan, O. [1 ]
Alajjuri, M. [2 ]
Abusamra, R. [3 ]
Mundada, V [4 ]
机构：
[1] Amer Hosp Dubai, Pediat Pulmonol, Dubai, U Arab Emirates
[2] Univ Sharjah, Sharjah, U Arab Emirates
[3] Mediclin Hosp Dubai, Pediat Pulmonol, Dubai, U Arab Emirates
[4] Medcare Hosp Dubai, Pediat Neurol, Dubai, U Arab Emirates
来源：
PEDIATRIC PULMONOLOGY | 2023年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
H 139
引用
收藏
页码：S119 / S120
页数：2
相关论文
共 50 条
  • [1] Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy in Patients with Spinal Muscular Atrophy Type 1
    Mendell, Jerry
    Wigderson, Melissa
    Alecu, Iulian
    Yang, Lina
    Mehl, Lesa
    Connolly, Anne
    NEUROLOGY, 2023, 100 (17)
  • [2] Long-term follow-up of onasemnogene abeparvovec gene therapy in patients with spinal muscular atrophy (SMA) type 1
    Mendell, J.
    Wigderson, M.
    Alecu, I.
    Yang, L.
    Mehl, L.
    Connolly, A.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S91 - S91
  • [3] Long-term follow-up of onasemnogene abeparvovec gene therapy in spinal muscular atrophy type 1 (SMA1)
    Mendell, J.
    Shell, R.
    Lehman, K.
    McColly, M.
    Lowes, L.
    Alfano, L.
    Miller, N.
    Iammarino, M.
    Church, K.
    Ogrinc, F.
    Ouyang, H.
    Kernbauer, E.
    Joshi, S.
    Sproule, D.
    Meriggioli, M.
    Feltner, D.
    Al-Zaidy, S.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S122 - S123
  • [4] LONG-TERM FOLLOW-UP OF THE PHASE 1 START TRIAL OF ONASEMNOGENE ABEPARVOVEC GENE THERAPY IN SPINAL MUSCULAR ATROPHY TYPE 1
    Mendell, J. R.
    Shell, R.
    Lehman, K. J.
    McColly, M.
    Lowes, L. P.
    Alfano, L. N.
    Miller, N. F.
    Iammarino, M. A.
    Church, K.
    Kausar, I.
    Reyna, S. P.
    Meriggioli, M.
    Kleyn, A.
    Al-Zaidy, S.
    THORAX, 2021, 76 : A10 - A10
  • [5] Long-term follow-up (LTFU) of onasemnogene abeparvovec gene therapy in spinal muscular atrophy (SMA)
    Mendell, J.
    Finkel, R.
    Mercuri, E.
    Strauss, K.
    Day, J.
    Kleyn, A.
    Chand, D.
    Tauscher-Wisniewski, S.
    Meriggioli, M.
    NEUROMUSCULAR DISORDERS, 2021, 31 : S132 - S133
  • [6] Long-term Follow-up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
    Day, J.
    Mendell, J.
    Finkel, R.
    Mercuri, E.
    Strauss, K.
    Kleyn, A.
    Chand, D.
    Tauscher-Wisniewski, S.
    Meriggioli, M.
    ANNALS OF NEUROLOGY, 2021, 90 : S151 - S152
  • [7] Long-Term Follow-Up (LTFU) of Onasemnogene Abeparvovec Gene Therapy in Spinal Muscular Atrophy (SMA)
    Mendell, Jerry
    Finkel, Richard
    Mercuri, Eugenio
    Strauss, Kevin
    Day, John
    Kleyn, Aaron
    Chand, Deepa
    Tauscher-Wisniewski, Sitra
    Meriggioli, Matthew
    NEUROLOGY, 2021, 96 (15)
  • [8] Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy
    Stevens, Debra
    Claborn, Melanie K.
    Gildon, Brooke L.
    Kessler, Tiffany L.
    Walker, Cheri
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (10) : 1001 - 1009
  • [9] Ethical issues related to gene therapy with onasemnogene abeparvovec for spinal muscular atrophy type 1 in a developing country
    Thong, Meow-Keong
    Tae, Sok-Kun
    Mazlan, Rifhan
    Fong, Choong Yi
    Marie, Nathan Anna
    Li, Limin
    Lim, Wei-Kang
    Eg, Kah-Peng
    GENETICS IN MEDICINE, 2022, 24 (03) : S274 - S275
  • [10] Acute Benign Myositis Following Onasemnogene Abeparvovec Therapy in Type 1 Spinal Muscular Atrophy
    Dosi, Claudia
    Tozzo, Alessandra
    Masson, Riccardo
    PEDIATRIC NEUROLOGY, 2022, 131 : 23 - 24
12345